| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 08/05/2004 | WO2004032861A3 Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents |
| 08/05/2004 | WO2004030614A3 Vaccines containing viruses involved in avian malabsorption syndrome and methods of administration therefor |
| 08/05/2004 | WO2004024077A9 Novel composition and methods for the treatment of psoriasis |
| 08/05/2004 | WO2004024071A3 A composition for treating aids and associated conditions |
| 08/05/2004 | WO2004024070A3 Factors that bind intestinal toxins |
| 08/05/2004 | WO2004012680B1 Lipid-drug complexes in reversed liquid and liquid crystalline phases |
| 08/05/2004 | WO2003084465A3 Modeling biological systems |
| 08/05/2004 | US20040153127 Treatments for snoring using injectable neuromuscular stimulators |
| 08/05/2004 | US20040152889 Process for the preparation of benazepril |
| 08/05/2004 | US20040152779 Bicyclic amino acids as pharmaceutical agents |
| 08/05/2004 | US20040152777 Therapeutically active compounds |
| 08/05/2004 | US20040152771 Mixture with biguanidine drug; antidiabetic agents; insulin resistance |
| 08/05/2004 | US20040152624 Oral lactoferrin in the treatment of sepsis |
| 08/05/2004 | US20040152172 Generating pool of RNA interfering sequences via transformation, expression and recovery of cloned vector sequences associated with full hairpin random oligonucleotides; gene expression inhibition |
| 08/05/2004 | US20040152140 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 08/05/2004 | US20040152139 for diagnosing/treating prostate cancer by administering immunoconjugates; gene expression inhibition; genetic engineering |
| 08/05/2004 | US20040152111 Compositions and methods for diagnosing and treating mood disorders |
| 08/05/2004 | US20040151793 Onion extract can be integrated into base containing oil without effectiveness being reduced or phase separation being produced |
| 08/05/2004 | US20040151789 Herbal compositions for the treatment of mucosal lesions |
| 08/05/2004 | US20040151787 Water soluble compositions derived from plant material and preparation thereof |
| 08/05/2004 | US20040151758 fatty acids whose yield energy from beta-oxidation is sufficiently low so that the compound is rendered metabolically low caloric or non-caloric, or a physiologically acceptable ester thereof or a metabolic precursor thereof |
| 08/05/2004 | US20040151722 Treatment of metabolic disorders using TNFalpha inhibitors |
| 08/05/2004 | US20040151680 in a carrier which is an anhydrous pigmented composition or an emulsion; improving shine, payoff, and feel; |
| 08/05/2004 | US20040148711 Dye composition for keratin fibers, with a cationic direct dye and a substantive polymer |
| 08/05/2004 | DE10301592A1 Verwendung von an GSTM bindenden Substanzen zur Diagnose und Behandlung des Harnblasenkarzinoms Use of binding substances to GSTM for the diagnosis and treatment of bladder cancer |
| 08/05/2004 | DE10301371A1 Treatment or prophylaxis of cardiovascular, cardiopulmonary or renal diseases, e.g. hypertension combined with hyperlipidemia or atherosclerosis, using combination of telmisartan and atorvastatin |
| 08/05/2004 | CA2802143A1 Cancer therapy sensitizer |
| 08/05/2004 | CA2516116A1 Nanoparticle based stabilization of ir fluorescent dyes |
| 08/05/2004 | CA2514479A1 Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof |
| 08/05/2004 | CA2514130A1 Therapeutically active compounds |
| 08/05/2004 | CA2514126A1 Fat substitutes |
| 08/05/2004 | CA2514024A1 Treating androgen deficiency in female (adif)-associated conditions with sarms |
| 08/05/2004 | CA2513584A1 The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors |
| 08/05/2004 | CA2513575A1 Treatment of benign prostatic hyperplasia using energolytic agents |
| 08/05/2004 | CA2513572A1 Treatment of benign prostatic hyperplasia |
| 08/05/2004 | CA2513571A1 The use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| 08/05/2004 | CA2513559A1 Herpesvirus amplicon particles |
| 08/05/2004 | CA2513470A1 Modulation of deubiquitinase family members |
| 08/05/2004 | CA2513331A1 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| 08/05/2004 | CA2513320A1 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 08/05/2004 | CA2513184A1 Substrate detection assay |
| 08/05/2004 | CA2513182A1 Inhibition of e3-ubiquitin ligase hakai for treatment of proliferative disorders |
| 08/05/2004 | CA2513004A1 Aptamer therapeutics useful in ocular pharmacotherapy |
| 08/05/2004 | CA2512786A1 Methods and dosage forms with modified viscosity layers |
| 08/05/2004 | CA2512704A1 Geminally di-substituted nsaid derivatives as abeta 42 lowering agents |
| 08/05/2004 | CA2512546A1 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/05/2004 | CA2511570A1 Composition and method for preventing or treating a virus infection |
| 08/04/2004 | EP1441747A2 Use of an extract from the vigna aconitifolia plant in a cosmetic and/or dermopharmaceutical composition |
| 08/04/2004 | EP1441741A1 Rehydrating formulation |
| 08/04/2004 | EP1441698A1 Flashmelt oral dosage formulation |
| 08/04/2004 | EP1441682A1 Method to induce neovascular formation and tissue regeneration |
| 08/04/2004 | CN1518543A Pyrazole derivatives and their use as protein kinase inhibitors |
| 08/04/2004 | CN1518542A Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes |
| 08/04/2004 | CN1518462A Pharmaceutical formulation |
| 08/04/2004 | CN1160333C Ester of pipperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 110,907 |
| 08/04/2004 | CN1160081C Combination therapy of HIV infection using HIV protease inhibitior induinavir and reverse transcriptase inhibitor 3TC, optionally together with AZT, DDI or DDC |
| 08/04/2004 | CN1160054C Gel cleanser composition |
| 08/04/2004 | CN1160050C Desensitizing dentifrice having limited astringercy |
| 08/04/2004 | CN1160048C Hair-conditioning product |
| 08/03/2004 | US6770768 Lowers ldl cholesterol levels in serum and which is fat soluble beta - sitostanol fatty acid ester, and to a method for preparing and using the same. the substance can be taken orally as a food additive, food substitute or supplement. |
| 08/03/2004 | US6770635 Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions |
| 08/03/2004 | US6770295 Once-daily administration form, while maintaining the desired effect on the bladder, indeed gives a significant reduction of the (already low) side-effects, particularly dry mouth |
| 08/03/2004 | CA2310207C Topical zinc compositions and methods of use |
| 07/29/2004 | WO2004062629A2 Apoptolidin analogs and derivatives for inducing apoptosis in transformed cells |
| 07/29/2004 | WO2004062628A2 Gilsonite derived pharmaceutical delivery compositions and methods |
| 07/29/2004 | WO2004062627A2 In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders |
| 07/29/2004 | WO2004062623A2 Method of treating functional bowel disorders |
| 07/29/2004 | WO2004062621A2 Anti-inflammatory agents and methods of their use |
| 07/29/2004 | WO2004062620A2 Paricalcitol as a chemotherapeutic agent |
| 07/29/2004 | WO2004062619A2 SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF |
| 07/29/2004 | WO2004062618A2 Method for in vivo regulation of cardiac muscle contractility |
| 07/29/2004 | WO2004062616A2 Method of treating cognitive decline due to sleep deprivation and stress |
| 07/29/2004 | WO2004062615A2 Tactile agents |
| 07/29/2004 | WO2004062613A2 Hiv integrase inhibitors |
| 07/29/2004 | WO2004062606A2 Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal |
| 07/29/2004 | WO2004062603A2 Methods of treating lung diseases |
| 07/29/2004 | WO2004062602A2 Compositions and methods for targeted biological delivery of molecular carriers |
| 07/29/2004 | WO2004062600A2 Antiviral patch |
| 07/29/2004 | WO2004062597A2 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| 07/29/2004 | WO2004062596A2 Antineoplastic ether lipid compounds having a four carbon backbone |
| 07/29/2004 | WO2004062593A2 Antineoplastic ether lipid compounds with modifications at the sn-2 carbon |
| 07/29/2004 | WO2004062592A2 2-o sulfatase compositions and related methods |
| 07/29/2004 | WO2004062591A2 Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases |
| 07/29/2004 | WO2004062590A2 Bicyclic carbohydrates as antiprotozoal bioactive for the treatment of infections caused by parasites |
| 07/29/2004 | WO2004062588A2 Water-soluble polymeric bone-targeting drug delivery system |
| 07/29/2004 | WO2004062587A2 Night-time oral insulin therapy |
| 07/29/2004 | WO2004062586A2 Antineoplastic ether lipid compounds |
| 07/29/2004 | WO2004062584A2 Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection |
| 07/29/2004 | WO2004062582A2 Combination therapy for anticoagulation |
| 07/29/2004 | WO2004062578A2 Methods for reducing mortality associated with acute myocardial infarction |
| 07/29/2004 | WO2004062576A2 Methods for treating ocular diseases |
| 07/29/2004 | WO2004062573A2 Oral-care device and system |
| 07/29/2004 | WO2004062571A2 Substantially pure cilostazol and processes for making same |
| 07/29/2004 | WO2004062570A2 Apparatus and method to measure platelet contractility |
| 07/29/2004 | WO2004062566A2 Polyherbal preparation for the prevention of atherosclerosis and hyperlipidemia |
| 07/29/2004 | WO2004062562A2 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 07/29/2004 | WO2004062560A2 Pharmaceutical composition |
| 07/29/2004 | WO2004062558A2 Process for enzymatic synthesis of βετα-lactam antibiotics |
| 07/29/2004 | WO2004062557A2 Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 07/29/2004 | WO2004062551A2 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |